NIH’s candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
One thousand times more soluble than L-cystine at neutral pH
IIT Kanpur pioneers ground-breaking gene therapy technology for Hereditary Eye Diseases
Julian Collins, Jana Windt and Michiel Stork join biopharma company’s leadership team
With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
The expansion makes Exothera one of the largest viral vector facilities in Europe
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
Subscribe To Our Newsletter & Stay Updated
